

Special 510(k) Submission – Additions to UNIPLATE Anterior Cervical Plate System

5. **510(K) SUMMARY**

SEP 1 0 2008

Submitter: DePuy Spine, Inc.
325 Paramount Drive
Raynham, MA 02767

Contact Person: Frank Jurczak
Regulatory Affairs Associate
Voice: (508) 828-3288
Fax: (508) 828-3797
E-Mail: fjurczak@dpyus.jnj.com

Date Prepared: August 8, 2008

Device Class: Class II

Classification Name: Spinal intervertebral body fixation orthosis
per 21 CFR §888.3060

Classification Panel: Orthopedics

FDA Panel Number: 87

Product Code(s): KWQ

Proprietary Name: UNIPLATE Anterior Cervical Plate System

Predicate Devices: UNIPLATE Anterior Cervical Plate System (K042544)
EAGLE Anterior Cervical Plate System (K040197)

Device Description: The UNIPLATE Anterior Cervical Plate System consists of
an assortment of plates and screws

The UNIPLATE Anterior Cervical Plate System also
contains Class I manual surgical instruments and cases that
are considered exempt from premarket notification.

Intended Use: The UNIPLATE Anterior Cervical Plate System is intended
for anterior cervical intervertebral body fixation. This
system is indicated for patients in which stability is desired
following anterior cervical fusion for the indications listed
below. The intended levels for treatment range from C2-T1.

Special 510(k) Submission - Additions to UNIPLATE Anterior Cervical Plate System

Indications include symptomatic cervical spondylosis, trauma, fracture, post-traumatic kyphosis or lordosis, tumor, degenerative disc disease (defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies), spinal stenosis, re-operation for failed fusion, or instability following surgery for the above indications.

Materials: Manufactured from ASTM F 136 implant grade titanium alloy.

Performance Data: Performance data per ASTM F 1717 were submitted to characterize the subject UNIPLATE Anterior Cervical Plate System components addressed in this notification.



SEP 10 2008

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Depuy Spine, Inc.
% Mr. Frank Jurczak
Regulatory Affairs Associate
325 Paramount Drive
Raynham, Massachusetts 02767

Re: K082273
Trade/Device Name: UNIPLATE Anterior Cervical Plate System
Regulation Number: 21 CFR 888.3060
Regulation Name: Spinal intervertebral body fixation orthosis.
Regulatory Class: II
Product Code: KWQ
Dated: August 08, 2008
Received: August 11, 2008

Dear Mr. Jurczak:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

4. INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K082273

Device Name: UNIPLATE Anterior Cervical Plate System

Indications For Use:

The UNIPLATE Anterior Cervical Plate System is intended for anterior cervical intervertebral body fixation. This system is indicated for patients in which stability is desired following anterior cervical fusion for the indications listed below. The intended levels for treatment range from C2-T1.

Indications include symptomatic cervical spondylosis, trauma, fracture, post-traumatic kyphosis or lordosis, tumor, degenerative disc disease (defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies), spinal stenosis, re-operation for failed fusion, or instability following surgery for the above indications.


Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices

510(k) Number K082273